Manchester Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $292K | Hold |
1,910
| – | – | 0.04% | 224 |
|
|
2025
Q4 | $263K | Buy |
1,910
+1,463
| +327% | +$192K | 0.04% | 235 |
|
|
2025
Q3 | $57.3K | Buy |
447
+9
| +2% | +$1.1K | 0.01% | 536 |
|
|
2025
Q2 | $53K | Buy |
438
+23
| +6% | +$2.59K | 0.01% | 557 |
|
|
2025
Q1 | $46.3K | Hold |
415
| – | – | 0.01% | 564 |
|
|
2024
Q4 | $40.4K | Hold |
415
| – | – | ﹤0.01% | 580 |
|
|
2024
Q3 | $47.7K | Hold |
415
| – | – | 0.01% | 547 |
|
|
2024
Q2 | $44.2K | Hold |
415
| – | – | 0.01% | 522 |
|
|
2024
Q1 | $40.1K | Sell |
415
-1
| -0.2% | -$103 | ﹤0.01% | 495 |
|
|
2023
Q4 | $42K | Buy |
416
+75
| +22% | +$7.24K | 0.01% | 451 |
|
|
2023
Q3 | $34.7K | Buy |
341
+33
| +11% | +$3.35K | 0.01% | 462 |
|
|
2023
Q2 | $31.1K | Buy |
308
+219
| +246% | +$21.9K | ﹤0.01% | 452 |
|
|
2023
Q1 | $8.19K | Sell |
89
-53
| -37% | -$4.63K | ﹤0.01% | 568 |
|
|
2022
Q4 | $12.9K | Buy |
142
+63
| +80% | +$5.31K | ﹤0.01% | 445 |
|
|
2022
Q3 | $6K | Hold |
79
| – | – | ﹤0.01% | 498 |
|
|
2022
Q2 | $7K | Hold |
79
| – | – | ﹤0.01% | 522 |
|
|
2022
Q1 | $7K | Buy |
79
+26
| +49% | +$2.25K | ﹤0.01% | 597 |
|
|
2021
Q4 | $5K | Sell |
53
-868
| -94% | -$72.1K | ﹤0.01% | 671 |
|
|
2021
Q3 | $75K | Buy |
921
+852
| +1,235% | +$76.6K | 0.01% | 390 |
|
|
2021
Q2 | $6K | Buy |
69
+16
| +30% | +$1.43K | ﹤0.01% | 555 |
|
|
2021
Q1 | $5K | Hold |
53
| – | – | ﹤0.01% | 535 |
|
|
2020
Q4 | $5K | Buy |
+53
| New | +$4.63K | ﹤0.01% | 536 |
|
|
2016
Q2 | – | Sell |
-151
| Closed | -$10K | – | 560 |
|
|
2016
Q1 | $10K | Hold |
151
| – | – | ﹤0.01% | 528 |
|
|
2015
Q4 | $12K | Hold |
151
| – | – | ﹤0.01% | 598 |
|
|
2015
Q3 | $12K | Hold |
151
| – | – | ﹤0.01% | 579 |
|
|
2015
Q2 | $13K | Hold |
151
| – | – | ﹤0.01% | 501 |
|
|
2015
Q1 | $13K | Sell |
151
-4,845
| -97% | -$430K | ﹤0.01% | 484 |
|
|
2014
Q4 | $415K | Sell |
4,996
-1,641
| -25% | -$136K | 0.05% | 195 |
|
|
2014
Q3 | $560K | Buy |
6,637
+569
| +9% | +$46K | 0.07% | 122 |
|
|
2014
Q2 | $492K | Buy |
6,068
+5,658
| +1,380% | +$445K | 0.07% | 152 |
|
|
2014
Q1 | $31K | Buy |
410
+151
| +58% | +$11K | 0.01% | 713 |
|
|
2013
Q4 | $19K | Sell |
259
-70
| -21% | -$4.87K | ﹤0.01% | 727 |
|
|
2013
Q3 | $23K | Hold |
329
| – | – | ﹤0.01% | 729 |
|
|
2013
Q2 | $21K | Buy |
+329
| New | +$21.4K | ﹤0.01% | 738 |
|
Other funds holding NVS
Manchester Capital Management's NVS Position: Q1 2026 in Review
Manchester Capital Management held its Novartis (NVS) position steady in Q1 2026 at 1,910 shares worth $292K. The position accounts for 0.04% of the portfolio, ranked #224.
Manchester Capital Management first reported a position in NVS in Q2 2013 and has held it in 34 quarters since. The position peaked at $560K in Q3 2014. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Manchester Capital Management held 1,910 shares of Novartis worth $292K as of Q1 2026.
- Manchester Capital Management left its Novartis share count unchanged in Q1 2026.
- Novartis made up 0.04% of Manchester Capital Management's portfolio in Q1 2026, its #224 holding.
- Manchester Capital Management first reported a position in Novartis in Q2 2013 and has held it in 34 quarters since.
- Manchester Capital Management's Novartis position peaked at $560K in Q3 2014.
- 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.